Francesco Grossi - Concepedia

Author

Francesco Grossi

Also Known As

E Baldini, F GROSSI, F Grossi, F. Grossi, FRANCESCO GROSSI, Federico Cappuzzo, Francesco Grossi, G D Beretta, Grossi, Grossi F

697

Publications

21.6K

Citations

H-Index

154

Concepts

All Affiliations

Ospedale Policlinico San Martino Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori University of Genoa

About

Francesco Grossi is an author at Ospedale Policlinico San Martino specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	77	5.6K
2	Health Sciences	12	19	1.1K
3	Engineering	6	6	288
4	Arts	1	1	15
5	Language Studies	1	1	56

Francesco Grossi

162

Publications

18K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial Paul Baas, Arnaud Scherpereel, Anna K. Nowak, The Lancet Checkmate 743MedicinePathologyPleural DiseaseCancer Treatment	2021	1.1K
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Journal of Clinical Oncology	2020	1.1K
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang, The Lancet Oncology Virus EpidemiologyMedicineCovid-19 PandemicClinical EpidemiologyInternational Health	2020	621
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza, Journal of Clinical Oncology	2023	549
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Journal of Clinical Oncology Cp ChemotherapyMedicinePhase IiiPharmacologyClinical Trials	2010	453
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis Biagio Ricciuti, Carlo Genova, Andrea De Giglio, Journal of Cancer Research and Clinical Oncology MedicineImmunologyMulti-institutional AnalysisImmune Checkpoint InhibitorBronchial Neoplasm	2018	357
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma Giovanni Luca Ceresoli, Paolo Andrea Zucali, Adolfo Favaretto, Journal of Clinical Oncology	2006	293
IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer Rita Rotondo, Gaia Barisione, Luca Mastracci, International Journal of Cancer	2009	196
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients Maria Giovanna Dal Bello, Rosangela Filiberti, Angela Alama, Journal of Translational Medicine	2019	193

Page 1